Aplisol Purple Book BLA 103782

BLA number
103782
Proprietary names
Aplisol
Proper names
Tuberculin, Purified Protein Derivative
Applicant
Endo Operations Limited, Par Pharmaceutical Companies, Inc.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001AplisolTuberculin, Purified Protein Derivative351(a)5TU/.1MLInjectionIntradermalMulti-Dose VialRxLicensed1998-04-20
002AplisolTuberculin, Purified Protein Derivative351(a)250TU/MLInjectionIntradermalMulti-Dose VialRxLicensed1998-04-20

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-07-01U001Aplisol351(a)RxEndo Operations Limited
2022-01-01U001Aplisol351(a)RxPar Pharmaceutical Companies, Inc.
2021-09-01U001Aplisol351(a)RxPar Pharmaceutical Companies, Inc.
2021-05-01U001Aplisol351(a)RxPar Pharmaceutical Companies, Inc.
2021-05-01U002Aplisol351(a)RxPar Pharmaceutical Companies, Inc.
2020-08-01R001Aplisol351(a)RxPar Pharmaceutical Companies, Inc.
2020-08-01R002Aplisol351(a)RxPar Pharmaceutical Companies, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Aplisol351(a)RxLicensed1998-04-20
2020-08-01002Aplisol351(a)RxLicensed1998-04-20